Legend biotech's (LEGN.US) CAR-T product sales in the second quarter reached $0.186 billion.

Legend biotech (LEGN.US) announced that according to the cooperation and license agreement signed with Johnson & Johnson on December 21, 2017, Legend Biotech announced on July 17, 2024, that the net sales of CAR-T therapy CARVYKTI were approximately 0.186 billion US dollars for the quarter ended June 30, 2024.

Gelonghui FinanceJul 17 20:02

Genscript Biotech Unit Logs $186 Million in Net Trade Sales From Carvykti in April-June

Genscript Biotech's (HKG:1548) US-listed unit Legend Biotech logged $186.0 million in net trade sales of its Carvykti drug in the three months through June 30, according to a Wednesday filing with

MT Newswires11:01

Express News | Legend Biotech Corp -Announced Carvykti Generated About $186 Mln in Net Trade Sales During the Quarter Ended June 30, 2024

BreakingsJul 17 19:32

J&J Beats in Q2 as Pharma Segment Outperforms

Seeking AlphaJul 17 19:16

Hong Kong stock market news | Genscript Bio (01548) fell more than 4%, with a total market value of over 25 billion Hong Kong dollars. Reports suggest that Legend Biotech may have received a takeover offer.

Genscript Bio (01548) fell more than 4%, and as of press time, it fell by 3.67% to HKD 12.08, with a turnover of 0.168 billion HKD, and a total market value exceeding 25 billion HKD.

Zhitong FinanceJul 16 10:07

The Latest Analyst Ratings For Legend Biotech

In the preceding three months, 15 analysts have released ratings for Legend Biotech (NASDAQ:LEGN), presenting a wide array of perspectives from bullish to bearish.The table below summarizes their

BenzingaJul 16 01:00